Lacosamide for the prevention of partial onset seizures in epileptic adults
Anna Kelemen1, Péter Halász21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, Pázmány Péter Catholic University, Budapest, Hungary Abstract: Lacosamide is a newly re...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/56c1ce2899e84c369f380d92a5d28782 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Anna Kelemen1, Péter Halász21National Institute of Neurosciences, Epilepsy Center, Budapest, Hungary; 2Faculty of Information Technology, Pázmány Péter Catholic University, Budapest, Hungary Abstract: Lacosamide is a newly registered antiepileptic drug with dual mechanisms of action. It selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. It also binds to a collapsing-response mediator protein-2, CRMP2. Lacosamide has a favorable pharmacokinetic profile; is rapidly and completely absorbed, has a relatively long elimination half-life of 13 hours which allows twice-daily administration, linear pharmacokinetics, and has low potential for drug interactions and renal elimination. Both oral and intravenous formulations of lacosamide are being developed. In placebo-controlled clinical trials, lacosamide was effective in seizure reduction as adjunctive therapy in patients with uncontrolled partial-onset seizures. Lacosamide was generally well tolerated. The most frequently reported adverse events in placebo-controlled trials were dizziness, headache, nausea, and diplopia. Intravenous lacosamide has a comparably good safety profile.Keywords: lacosamide, epilepsy, partial onset seizures |
|---|